ET-02

Last updated

ET-02
Clinical data
Other namesET02; RS-5441; RS5441
Routes of
administration 		Oral, topical [1]
Drug class Undefined (but targets and restores hair follicle stem cells) [1]

ET-02, also known as RS-5441, is a drug which is under development for the treatment of alopecia and hair disorders. [1] [2] [3] It is taken orally or topical, with both routes being developed. [1] The drug's exact mechanism of action has not yet been disclosed. [1] In any case, it is said to target and restore hair follicle stem cells (HFSCs). [3] ET-02 was originated by Renascience and is now under development by Eirion Therapeutics. [3] [1] [2] As of July 2025, it is in phase 1 clinical trials for alopecia and no recent development has been reported for hair disorders. [1] [2] The drug was reported to promote significant hair growth after 4 weeks of treatment in humans in a phase 1 trial and to do so more rapidly than minoxidil. [3] [1] As with its mechanism of action, the chemical structure of ET-02 does not yet appear to have been disclosed. [1]

See also

References

  1. 1 2 3 4 5 6 7 8 9 "RS 5441". AdisInsight. 28 July 2025. Retrieved 22 September 2025.
  2. 1 2 3 "Delving into the Latest Updates on ET-02(Eirion Therapeutics) with Synapse". Synapse. 20 September 2025. Retrieved 22 September 2025.
  3. 1 2 3 4 Bosslett M, Edelson J (14 January 2025). "The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia". Dermatology Times. Retrieved 22 September 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.